デフォルト表紙
市場調査レポート
商品コード
1138318

単核球症診断の世界市場-2022-2029

Global Mononucleosis Diagnostic Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
単核球症診断の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

世界の伝染性単核球症診断市場は、伝染性単核球症(IM)の発生率の上昇、単核球症に対する認識と知識の向上、IM治療のための研究開発活動の増加などの要因によって成長しています。

伝染性単核球症の調査、単核球症に対する認識・知識の向上、単核球症治療の研究開発の増加が、市場成長の原動力になると予想されます。

感染性単核球症(IM)の発生率の上昇、単核球症に関する認識と知識の高まり、IM診断と治療のための研究開発活動の増加は、世界の単核球症診断市場を拡大している主要因となっています。

また、既に市場に存在するものと比較して、より迅速に感染症を診断できる様々な新しい技術的進歩が起こっています。例えば、2020年にロシュは、EBV Epstein-Barr Virusの診断のために米国で1番目の体外定量診断検査であるCobas EBVテストをUSFDAが承認したことを発表しました。これは、ヘルスケア業界や専門家にとって非常に大きな成功であり、短時間で多くの検査を実施できるため、このウイルスのリスクを抱える患者を容易にモニターできるようになります。

単核球症は10代の若者や成人の間で最もよく見られる病気であるため、世界的に青少年人口が増加していることも、市場の成長につながる大きな要因の1つとなっています。世界の青少年人口の半数以上がアジアに居住しています。南アジアには、他のどの地域よりも多い3億5,000万人近い青少年がいます。次いで、東アジア・太平洋地域が3億人超となっています。これらの地域の青少年人口は、世界の他のどの地域よりも少ないのです。世界保健機関(WHO)の報告によると、世界には12億人近くの青少年(10~19歳)がいます。国によっては、青少年が人口の4分の1を占め、10~19歳の90%近くが住む低・中所得国(LMICs)を中心に、2050年まで青少年の数が増加すると予測されています。

単核球症の診断に利用可能な検査の限界は、市場成長の妨げになると予想されます。

単核球症診断検査にはいくつかの制限があり、予測期間中の市場成長の妨げになると予想されます。単核症を診断できる検査は3つしかなく、感染性単核症の成長速度からすると非常に低いものです。

産業分析

単核球症診断の世界市場は、ポーターのファイブフォース分析、規制分析、サプライチェーン分析、製品の革新、アンメットニーズなどの様々な業界要因に基づいて、市場の詳細な分析を提供します。

世界の単核球症診断市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 伝染性単核球症(IM)の発生率の上昇と単核球症に対する意識の高まり
    • 抑制要因
      • 抑制要因:単核球症の診断に利用可能な検査の限界
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 規制分析
  • サプライチェーン分析
  • 製品イノベーション
  • アンメットニーズ

第6章 検査タイプ別

  • エプスタインバーウイルス(EBV)抗体検査
  • モノスポットテスト
  • 完全血球計算検査

第7章 エンドユーザー別

  • 病院
  • ラボラトリー
  • その他

第8章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第9章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • テストタイプベンチマーキング
  • 注目の主要企業リスト

第10章 企業プロファイル

  • Bio-Rad Laboratories Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Thermo Fischer Scientific Inc.
  • Abbott Laboratories
  • Cardinal Health Inc.
  • Arlington Scientific Inc.
  • Quidel Corporation
  • Beckman Coulter Inc.
  • Immunostics Inc.
  • Meridian Bioscience
  • Sekisui Diagnostics

第11章 単核球症診断の世界市場-DataM

目次
Product Code: DMPH2195

Market Overview

The Global mononucleosis diagnostic market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.9 % during the forecast period (2022-2029).

Mono, or mononucleosis, is an acute infectious disease caused by the Epstein-Barr virus (EBV). People with mononucleosis often have a high fever, Laryngitis, hepatosplenomegaly, abnormal lymphocyte, and others. Most cases of mono are mild and can be treated easily. Adolescents and young adults (12 to 40 years old) are more likely to be affected. There are various detection tests used for the diagnosis of mononucleosis such as the complete blood count test, monospot test, and Epstein Barr virus (EBV) antibody test.

Market Dynamics

The global mononucleosis diagnostic market is growing owing to several factors including rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM treatment.

Rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM treatment are expected to drive market growth.

The rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM diagnosis and treatment are the major factors that are increasing the global mononucleosis diagnostic market.

Various novel technological advancements are taking place that can diagnose the infection faster as compared to already present in the market. For instance, in 2020, Roche announced that the USFDA has approved the Cobas EBV test that is the 1st in-vitro quantitative diagnostic test in US for the diagnosis of EBV Epstein-Barr Virus. This is very huge success for the healthcare industry and professionals as now it will be easy to monitor the patients at risk from this virus as it will conduct high number of tests in small duration of time.

Increasing adolescent population globally is also one of the major factors leading to growth of the market as mononucleosis is most common among teens and adults. More than half of all adolescents globally live in Asia. South Asia has nearly 350 million adolescents than any other region. It is followed by East Asia and the Pacific with over 300 million. The adolescent population of either of these regions are dwarfs that of any other region in the world. According to World Health Organization (WHO) report, there are nearly 1.2 billion adolescents (10-19 years old) worldwide. In some countries, adolescents account for a quarter of the population and the number of adolescents is expected to rise through 2050, mainly in low- and middle-income countries (LMICs) where close to 90% of 10- to 19-year-olds live.

Limitations of available tests for the diagnosis of mononucleosis is expected to hamper the market growth.

There are some limitations associated with mononucleosis diagnostic tests which are expected to hamper the market's growth over the forecast period. There are only three tests that can diagnose mononucleosis and that is very low in regard to the rate by which the infectious mononucleosis is growing.

Industry Analysis

The global mononucleosis diagnostic market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs

Segment Analysis

Monospot Test segment is expected to hold the largest market share in global mononucleosis diagnostic market

On the basis of test type, the mononucleosis diagnsotic market is segmented into Epstein Barr Virus (EBV) antibody test, monospot test, and complete blood count test. Among these, the monospot test segment accounted for the largest market share, owing to the several benefits associated with this test, such as accurate results, non-interference with other tests, cost-effectiveness, rapid detection of antibodies, among others. A monospot test is a quick screening test to detect a type of antibody (heterophil antibody) that forms during certain infections. This test is also used in the detection of other diseases with similar symptoms, such as cytomegalovirus infection, HIV, and strep throat. In this test, a blood sample is placed on a microscope slide and mixed with other substances. If heterophil antibodies are present, then the blood clumps (agglutinates), and indicates a mono infection. Monospot testing can usually detect antibodies 2 to 9 weeks after a person is infected. It typically is not used to diagnose mono that started more than 6 months earlier. Also, increase in awareness and knowledge regarding the disease are expected to drive the growth of this segment over the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mononucleosis diagnostic market

North America is dominating the global mononucleosis diagnostic market, and is expected to hold the highest market share over the forecast period, owing to rising incidence rate of infectious mononucleosis (IM), advancement in healthcare infrastructure supporting novel testing, and increasing research and development activities by major players in this region. Majority of the younger people in United States are infected with mononucleosis. According to the United States Census Bureau, there were 41,910,114 people aged between 10-19 in the United States, which is approx. 13% of the total population. Hence, with rising adolescent population this region, the market of mononucleosis diagnostic is growing rapidly.

On the other hand, the Asia-Pacific mononucleosis diagnostic market is growing at the fastest growth rate over the forecast period, owing to the rising adolescent population in this region. According to the UNICEF data, over half of all adolescents across the world live in Asia, and South Asia is home to the largest number of adolescents in any region in the world (around 340 million). South Asia is followed by East Asia and the Pacific, with around 277 million. Hence, due to increasing number of adolescents, huge opportunities are estimated to drive the growth of the market during the forecast period.

Competitive Landscape

The global mononucleosis diagnostic market is highly competitive with presence of smaller and major players. Some of the major players in the market include: Bio-Rad Laboratories Inc., Thermo Fischer Scientific Inc., Abbott Laboratories, Cardinal Health Inc., Arlington Scientific Inc., Quidel Corporation, Beckman Coulter Inc., Immunostics Inc., Meridian Bioscience, Sekisui Diagnostics, among others.

The key players are adopting various growth strategies such as Test Type launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the mononucleosis diagnostic market globally. For instance, in September 2019, Roche launched two tests, for use on the automated cobas 6800/8800 Systems in countries accepting the CE mark. The cobas EBV (Epstein-Barr virus) and cobas BKV (BK virus) Tests provide reliable, standardized, high-quality results for clinical decision-making to help manage the risk of infection and improve the management of severely immunocompromised transplant patients.

In July 2019, NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, launched CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), which can cause infectious mononucleosis and other illnesses.

Key Companies to Watch

Bio-Rad Laboratories

Overview: Bio-Rad Laboratories is an American company that develops and manufactures various products with technological advancements for Clinical Diagnostics and Life Science research. It was founded in 1952 and is headquartered in Berkeley, California. This company operates worldwide.

Product Portfolio: PLATELIA™ EB-NA-1 IgG: This product is used for the detection of IgG and IgM antibodies that are specific to the EBV antigen. Platelia EBV EIA microplate technology is widely used for detection of infectious mononucleosis.

Key Developments: In Mar 2021, Bio-Rad Laboratory revealed its partnership with F. Hoffmann-La Roche AG

The global mononucleosis diagnostic market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of infectious mononucleosis (IM) and Growing awareness towards mononucleosis
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations of Available Tests for the Diagnosis of Mononucleosis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Regulatory Analysis
  • 5.3 Supply Chain Analysis
  • 5.4 Product Innovations
  • 5.5 Unmet Needs

6. By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 6.1.2. Market Attractiveness Index, By Test Type Segment
  • 6.2. Epstein Barr Virus (EBV) Antibody Test
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Monospot Test
  • 6.4. Complete Blood Count Test

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User Segment
  • 7.2. Hospitals
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Laboratories
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Italy
      • 8.3.5.5. Spain
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

  • 9.1. Key Developments and Strategies
  • 9.2. Company Share Analysis
  • 9.3. Test Types Benchmarking
  • 9.4. List of Key Companies to Watch

10. Company Profiles

  • 10.1 Bio-Rad Laboratories Inc.*
    • 10.1.1 Company Overview
    • 10.1.2 Product Portfolio and Description
    • 10.1.3 Key Highlights
    • 10.1.4 Financial Overview
  • 10.2 Thermo Fischer Scientific Inc.
  • 10.3 Abbott Laboratories
  • 10.4 Cardinal Health Inc.
  • 10.5 Arlington Scientific Inc.
  • 10.6 Quidel Corporation
  • 10.7 Beckman Coulter Inc.
  • 10.8 Immunostics Inc.
  • 10.9 Meridian Bioscience
  • 10.10 Sekisui Diagnostics

LIST NOT EXHAUSTIVE

11. Global Mononucleosis Diagnostic Market - DataM

  • 11.1. Appendix
  • 11.2. About Us and Distribution Channel
  • 11.3. Contact Us